Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates
Portfolio Pulse from
Arbutus Biopharma (ABUS) reported a Q3 loss of $0.10 per share, matching the Zacks Consensus Estimate, but lagged in revenue estimates. This is an improvement from the $0.12 per share loss a year ago.
November 06, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Arbutus Biopharma reported a Q3 loss of $0.10 per share, in line with expectations, but missed revenue estimates. This is an improvement from the previous year's $0.12 loss per share.
The earnings per share were in line with expectations, which is neutral for the stock price. However, missing revenue estimates could be a concern for investors, but the improvement from last year's loss per share may offset some negative sentiment.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100